Tenoten in the therapy of patients with moderate cognitive impairment

Bull Exp Biol Med. 2009 Aug;148(2):353-6. doi: 10.1007/s10517-009-0679-8.


Tenoten is a new anxiolytic and antidepressant based on antibodies to brain-specific protein S-100B. Experimental studies demonstrated the effect of tenoten on mechanisms of neuronal plasticity and manifestations of higher nervous activity. Tenoten is clinically comparable with amitryptiline, sertraline, and phenazepam, but does not produce potent sedative relaxation effect typical of these drugs. The study demonstrated considerable improvement of the control over brain frontal compartment effector functions. Tenoten is recommended not only at the stage of moderate cognitive impairment, but also in manifest cerebrovascular pathologies characterized by pronounced impairment of the regulatory functions of the frontal compartments of the brain.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Anti-Anxiety Agents / therapeutic use*
  • Antibodies / therapeutic use*
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / pathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Treatment Outcome


  • Anti-Anxiety Agents
  • Antibodies
  • tenoten